Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease

RTTNews | 688 dias atrás

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).

The company said an application for the SC administration of ENTYVIO for the treatment of adults with moderately to severely active ulcerative colitis (UC) is also under review by the FDA.

The BLA package for SC administration of ENTYVIO for the treatment of adults with moderately to severely active CD is based on data from VISIBLE, a pivotal Phase 3 clinical trial.

The trial assessed the safety and efficacy of an SC formulation of ENTYVIO as maintenance therapy compared to placebo in 409 adult patients with moderately to severely active CD who achieved clinical response at Week 6 following two doses of open-label vedolizumab IV therapy at Weeks 0 and 2.

Patients were randomized 2:1 to SC administration of ENTYVIO 108 mg or placebo every 2 weeks. Eligible patients had an inadequate response to or intolerance of corticosteroids, immunomodulators, and/or anti-tumor necrosis factor [TNF] therapies.

The primary endpoint was clinical remission [defined as CD Activity Index score =150] at Week 52.

For More Such Health News, visit rttnews.com

Etiquetas: TAK TKPHF.PK

Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

RTTNews | 536 dias atrás

Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA

Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).

RTTNews | 590 dias atrás

Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia

Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.

RTTNews | 676 dias atrás

Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis

Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.

RTTNews | 690 dias atrás

U.S. Construction Spending Unexpectedly Sees Further Downside In June

The Commerce Department released a report on Friday unexpectedly showing a continued decrease by U.S. construction spending in the month of June. The report said construction spending fell by 0.4 percent to an annual rate of $2.136 trillion in June after sliding by 0.5 percent to a revised rate of $2.144 trillion in May.

RTTNews | 18 minutos atrás

U.S. Consumer Sentiment Improves Marginally Less Than Previously Estimated In July

Revised data released by the University of Michigan on Friday showed consumer sentiment in the U.S. improved marginally less than previously estimated in the month of July. The University of Michigan said its consumer sentiment index for July was downwardly revised to 61.7 from a preliminary reading of 61.8. Economists had expected the index to be upwardly revised to 62.0.

RTTNews | 22 minutos atrás

U.S. Manufacturing Index Unexpectedly Dips To Nine-Month Low In July

Manufacturing activity in the U.S. unexpectedly contracted at a slightly faster rate in the month of July, according to a report released by the Institute for Supply Management on Friday. The ISM said its manufacturing PMI edged down to 48.0 in July after inching up to 49.0 in June with a reading below 50 indicating contraction.

RTTNews | 24 minutos atrás

Eurozone Inflation Steady At 2% ECB Target

Euro area consumer price inflation was unchanged at the European Central Bank's 2 percent target in July, easing the pressure for more easing. The harmonized index of consumer prices increased 2.0 percent year-on-year in July, the same rate of increase as seen in June. Inflation was forecast to ease marginally to 1.9 percent.

RTTNews | 1 h 11 min atrás

EURUSD	1.15531	GBPUSD	1.32651	AUDUSD	0.64669
USDJPY	148.092	USDCAD	1.37871	USDCHF	0.80666

Advertisement

Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease